CD133 in Breast Cancer Cells: More than a Stem Cell Marker

Brugnoli, Federica; Grassilli, Silvia; Al-Qassab, Yasamin; Capitani, Silvano; Bertagnolo, Valeria

doi:10.1155/2019/7512632

Cited by 89 publications

(71 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD133 is a stemness marker that is related to increased tumor-initiating ability, tumor progression, metastasis, therapeutic resistance, and cancer recurrence in numerous types of cancer [38]. Apparently, CD133 expression is not associated with invasiveness, as it is a malignancy indicator for both invasive and noninvasive breast cancers [39].…”

Section: Discussionmentioning

confidence: 99%

Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer

Savelieva

Таширева

Кайгородова

et al. 2020

IJMS

View full text Add to dashboard Cite

The presence of stem and epithelial–mesenchymal-transition (EMT) features in circulating tumor cells (CTCs) determines their invasiveness, adaptability to the microenvironment, and resistance to proapoptotic signals and chemotherapy. It also allows them to fulfil the role of metastatic “seeds”. We evaluated the heterogeneity of stem CTCs by their CD44, ALDH1, and CD133 expression depending on N-cadherin expression in breast-cancer patients. A total of 38 female patients were selected for this study. CTC phenotypes were determined by flow cytometry before any type of treatment. Multiplex immunofluorescence was used for the evaluation of tumor-cell heterogeneity in primary lesions. In patients who had CD44-CD24- CTCs, a subset of cells with the expression of other stem-cell markers (CD133 and ALDH1) were detected. Expression of CD133 and/or ALDH1 may be associated with expression of N-cadherin: all populations of N-cadherin+ CTCs demonstrate stem features; in the absence of N-cadherin expression, true nonstem (CD44-CD24-CD133-ALDH1-) cells are found. The heterogeneity of stem marker expression in CTCs was observed regardless of N-cadherin expression. In our study, stromal cell-derived factor-1 (SDF-1) receptor expression in CTCs did not depend on stemlike traits, but was instead associated with N-cadherin expression. Subpopulations of tumor cells, detected both in tumors and blood, were identified. Breast cancer was characterized by pronounced interpersonal and intrapersonal heterogeneity of CTCs by the presence and combination of various stem features and N-cadherin expression. To complete the characterization of stemlike features of CTCs, we suggest the simultaneous use of the three stem markers.

show abstract

Section: Discussionmentioning

confidence: 99%

Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer

Savelieva

Таширева

Кайгородова

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Correlations between THRβ1 expression and known clinicopathological characteristics, besides ER and PR, were also analyzed. CD133, a widely used marker for isolating cancer stem cells [31,32], and N-cadherin, a well-known marker for epithelial-to-mesenchymal transition [33], are associated with BC aggressiveness; we previously reported quantification of their expression in the same BC cohort [34]. As shown in Table 4, both nuclear and cytoplasmic THRβ1 expression were significantly and positively correlated with CD133 and N-cadherin (NCAD).…”

Section: Correlation With Clinicopathological Parametersmentioning

confidence: 94%

Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer

Shao¹,

Kühn²,

Mayr

et al. 2020

IJMS

View full text Add to dashboard Cite

The aim of this study was to investigate the expression of thyroid hormone receptor β1 (THRβ1) by immunohistochemistry in breast cancer (BC) tissues and to correlate the results with clinico-biological parameters. In a well-characterized cohort of 274 primary BC patients, THRβ1 was widely expressed with a predominant nuclear location, although cytoplasmic staining was also frequently observed. Both nuclear and cytoplasmic THRβ1 were correlated with high-risk BC markers such as human epidermal growth factor receptor 2 (HER2), Ki67 (also known as MKI67), prominin-1 (CD133), and N-cadherin. Overall survival analysis demonstrated that cytoplasmic THRβ1 was correlated with favourable survival (p = 0.015), whereas nuclear THRβ1 had a statistically significant correlation with poor outcome (p = 0.038). Interestingly, in our cohort, nuclear and cytoplasmic THRβ1 appeared to be independent markers either for poor (p = 0.0004) or for good (p = 0.048) prognosis, respectively. Altogether, these data indicate that the subcellular expression of THRβ1 may play an important role in oncogenesis. Moreover, the expression of nuclear THRβ1 is a negative outcome marker, which may help to identify high-risk BC subgroups.

show abstract

“…1 and Table 4). These correlations strongly suggest that only cytoplasmic PPARγ was associated with the more aggressive tumors, namely ER negative, HER2 positive, CD133 (as a CSC marker [33,34]) positive and NCAD (as an EMT marker [35]) positive sub-groups. Nonetheless, cytoplasmic PPARγ expression being much higher (15 fold) than nuclear one, total PPARγ expression exhibited similar association as cytoplasmic one with tumor aggressiveness.…”

Section: Discussionmentioning

confidence: 99%

“…We then analyzed the correlations between PPARγ or Cox expression and known clinicopathological characteristics (Table 4). We also quantified the expression of two aggressiveness markers, CD133, a widely used marker for isolating cancer stem cell (CSC) [33,34], and N-cadherin, a well-known marker for epithelial-tomesenchymal transition (EMT) [35]. Considering first nuclear PPARγ, significant negative correlations were observed with grade (as already illustrated in Fig.…”

Section: Correlation Between Pparγ Cox Expression and Clinicopatholomentioning

confidence: 99%

Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers

Shao¹,

Kühn²,

Mayr

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the expression of the nuclear receptor PPARγ, together with that of the cyclooxygenases Cox-1 and Cox-2, in breast cancer (BC) tissues and to correlate the data with several clinicobiological parameters including patient survival. Methods: In a well characterized cohort of 308 primary BC, PPARγ, Cox-1 and Cox-2 cytoplasmic and nuclear expression were evaluated by immunohistochemistry. Correlations with clinicopathological and aggressiveness features were analyzed, as well as survival using Kaplan-Meier analysis. Results: PPARγ was expressed in almost 58% of the samples with a predominant cytoplasmic location. Cox-1 and Cox-2 were exclusively cytoplasmic. Cytoplasmic PPARγ was inversely correlated with nuclear PPARγ and ER expression, but positively with Cox-1, Cox-2, and other high-risk markers of BC, e.g. HER2, CD133, and N-cadherin. Overall survival analysis demonstrated that cytoplasmic PPARγ had a strong correlation with poor survival in the whole cohort, and even stronger in the subgroup of patients with no Cox-1 expression where cytoplasmic PPARγ expression appeared as an independent marker of poor prognosis. In support of this cross-talk between PPARγ and Cox-1, we found that Cox-1 became a marker of good prognosis only when cytoplasmic PPARγ was expressed at high levels. Conclusion: Altogether, these data suggest that the relative expression of cytoplasmic PPARγ and Cox-1 may play an important role in oncogenesis and could be defined as a potential prognosis marker to identify specific high risk BC subgroups.

show abstract

CD133 in Breast Cancer Cells: More than a Stem Cell Marker

Cited by 89 publications

References 76 publications

Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer

Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer

Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer

Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers

Contact Info

Product

Resources

About